Veracyte Named a San Francisco Bay Space “High Office” for Eighth Consecutive 12 months | Enterprise
SOUTH SAN FRANCISCO, Calif .– (BUSINESS WIRE) – Nov. August 2021–
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, announced today that it has been named a Top Workplace by the Bay Area News Group for the eighth consecutive year.
The annual award is based solely on employee feedback collected through an anonymous third-party survey conducted by Energage, LLC, a leading provider of technology-based engagement tools. The survey measures 15 culture drivers that are critical to business success, including alignment, execution, and engagement.
The employees of Veracyte, who took part in the survey about the top jobs in 2021, rated the company as the best for the efficient and good completion of tasks, for the fact that executives who understand the processes in the company hold meetings that the Make good use of employees’ time, have strong cross-departmental coordination, step in the right direction and act according to strong values.
“The results of this survey suggest that Veracyte employees at all levels believe in the quality of our work, our leadership and our processes and believe in our strategy,” said Marc Stapley, Chief Executive Officer of Veracyte. “As we continue to expand globally, we are committed to ensuring that Veracyte remains a top job for each of our employees around the world. This has been a core Veracyte value since the company was founded in 2008 and will be critical to achieving our vision of improving outcomes for patients around the world every step of their journey. “
The Bay Area News Group released the full list of the winners of the Top Workplaces 2021 on Sunday, August 22nd. The list is available on the Bay Area News Group website.
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions and providing diagnostic and treatment decisions throughout the patient journey for cancer and other diseases. The company’s growing range of genome tests leverages advances in genomic science and technology so that patients can avoid risky and costly diagnostic procedures and reduce the time to appropriate treatment. The company’s tests for lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients, and its kidney cancer and lymphoma subtyping tests are under development, the latter as companion diagnostics. With Veracyte’s exclusive global license for a world-class diagnostic instrument platform, the company is able to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered and selected trademarks of Veracyte, Inc. and its affiliates in the USA countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the United States and select countries and is used by Veracyte under license.
Vice President for Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCES BIOTECHNOLOGY HUMAN RESOURCES ONCOLOGY HEALTH PROFESSIONAL SERVICES GENETICS
Copyright Business Wire 2021.
PUB: 8/23/2021 10:33 a.m. / DISC: 8/23/2021 10:33 a.m.
Copyright Business Wire 2021.
